Product Description
Paromomycin is an aminoglycoside that is active against Gram-negative and many Gram-positive bacteria as well as some protozoa and cestodes. It is out of use as an antibiotic but was licensed in 2007 in India as an effective, well tolerated and affordable treatment for visceral leishmaniasis (VL) at a dose of 11 mg/kg (base) for 21 days. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/18947845/)
Mechanisms of Action: Protein Synthesis Inhibitor,30S Ribosomal Subunit Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical,Intramuscular
FDA Designation: None *
Approval Status: Approved
Approved Countries: Austria | Bangladesh | Belgium | Canada | Colombia | Dominican Republic | Germany | Greece | India | Indonesia | Israel | Italy | Japan | Luxembourg | Malta | Poland | Slovenia | South Africa | Spain | Switzerland | United Kingdom | United States | Uruguay
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|